EU 3275065940

U014850-1

US006310069B1

(12) **United States Patent**
Lohray et al.

(10) **Patent No.: US 6,310,069 B1**
(45) **Date of Patent: Oct. 30, 2001**

(54) **HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES**

(75) Inventors: **Vidya Bhushan Lohray; Braj Bhushan Lohray; Rao Bheema Paraselli; Ranga Madhavan Gurram; Rajagopalan Ramanujam; Ranjan Chakrabarti; Sarma K. S. Pakala**, all of Hyderabad (IN)

(73) Assignees: **Dr. Reddy's Research Foundation**, Hyderabad (IN); **Reddy-Cheminor Inc.**, Ridgewood, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/535,387**

(22) Filed: **Mar. 24, 2000**

Related U.S. Application Data

(63) Continuation-in-part of application No. 08/884,816, filed on Jun. 30, 1997, now Pat. No. 5,985,884, which is a continuation-in-part of application No. 08/777,627, filed on Dec. 31, 1996, now Pat. No. 5,885,997.

(51) **Int. Cl.**[7] **A01K 31/505**; C07D 239/02; C07D 239/70

(52) **U.S. Cl.** **514/256**; 514/258; 514/259; 544/253; 544/298; 544/299; 544/301; 544/242

(58) **Field of Search** 544/253, 298, 544/299, 301; 514/256, 258, 259

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,342,771	8/1982	Schnur	424/263
4,367,234	1/1983	Schnur	424/272
4,725,610	2/1988	Meguro	514/369
4,873,255	10/1989	Yoshioka	514/369
5,002,953	3/1991	Hindley	513/275
5,036,079	7/1991	Clark	514/333
5,037,842	8/1991	Goldstein	514/375
5,130,379	7/1992	Clark	514/333
5,153,210	10/1992	Ainsworth	514/369
5,296,605	3/1994	De Nanteuil	546/369
5,330,999	7/1994	De Nanteuil	514/176
5,420,146	5/1995	Malamas	514/364
5,468,762	11/1995	Malamas	514/376
5,478,851	12/1995	Cantello	514/369
5,478,852	12/1995	Olefsky	514/369
5,478,853	12/1995	Regnier	514/369
5,480,896	1/1996	Malamas	514/364
5,498,621	3/1996	Dow	514/369
5,521,201	5/1996	Hindley	514/369
5,521,202	5/1996	Yano	514/369
5,710,152	1/1998	Nagao et al.	514/225.2

FOREIGN PATENT DOCUMENTS

570067	3/1985	(AU) .
008203A	2/1980	(EP) .
5355524	8/1984	(EP) .
0139421	5/1985	(EP) .

(List continued on next page.)

OTHER PUBLICATIONS

Hisatome et al. (CA 119:249760, abstract of Chem. Lett. (1993), (8), 1357–7022).*

Rise et al. (CA 112:98478, abstract of Acta Chem Scand. (1989), 43(5), 489–92).*

Khan A. et al. (CA 110:189240, abstract of Pharmazie (1988), 43(12), 864–865), 1993.*

Chemical Abstracts 93:168217v, 1980 Oct. 27, 1980.

Shukla, et al., Indian J. Chem. vol. 17B, Jun. 1979, p. 651–652.

Husain, et al., Pharmazie 37, H6 (1982) p. 408–410.

Khan et al., Pharmazie (1988) vol. 43 (12), p. 864–5.

G. De Nanteuil, "Euglygaemic and Biological Activities of Novel Thiazolidine–2,4–dione Derivatives" Arzneittel Forschung/Drug Design, vol. 45, No. II, 1995, p. 1176–1181.

Whitcomb, R. W., "Thiazolidnediones", Expert Opionion on Investigational Drugs, vol. 4, No. 12, Dec. 1995, p. 1299–1309.

English Translation of JP–A–0912575.

Behavioral Brain Research, 75 (1996) p. 1–11, Messier, et al.

(List continued on next page.)

Primary Examiner—Sabiha N. Qaz
(74) *Attorney, Agent, or Firm*—Ladas & Parry

(57) **ABSTRACT**

The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

(I)



2 Claims, No Drawings